Sharda Cropchem Ltd
Sharda Cropchem is principally engaged in export of agrochemicals (technical grade and formulations) and non-agro products such as conveyor belts, rubber belts/sheets, dyes and dye intermediates to various countries across the world.
- Market Cap ₹ 3,727 Cr.
- Current Price ₹ 413
- High / Low ₹ 580 / 318
- Stock P/E 27.2
- Book Value ₹ 234
- Dividend Yield 1.45 %
- ROCE 8.56 %
- ROE 6.65 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 18.5%
Cons
- The company has delivered a poor sales growth of 10.2% over past five years.
- Company has a low return on equity of 13.2% over last 3 years.
- Earnings include an other income of Rs.271 Cr.
- Company has high debtors of 205 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
556 | 541 | 769 | 934 | 1,129 | 1,470 | 1,604 | 1,616 | 2,033 | 2,946 | 3,313 | 2,603 | |
435 | 408 | 614 | 700 | 851 | 1,129 | 1,326 | 1,386 | 1,644 | 2,344 | 2,809 | 2,430 | |
Operating Profit | 121 | 132 | 156 | 235 | 279 | 341 | 278 | 230 | 389 | 603 | 504 | 173 |
OPM % | 22% | 24% | 20% | 25% | 25% | 23% | 17% | 14% | 19% | 20% | 15% | 7% |
19 | 35 | 24 | 63 | 56 | 33 | 56 | 130 | 81 | 48 | 173 | 271 | |
Interest | 0 | 5 | 7 | 7 | 8 | 14 | 19 | 15 | 14 | 13 | 18 | 2 |
Depreciation | 37 | 29 | 23 | 35 | 56 | 70 | 99 | 137 | 170 | 245 | 248 | 267 |
Profit before tax | 104 | 133 | 150 | 256 | 270 | 290 | 217 | 209 | 285 | 392 | 411 | 175 |
Tax % | 32% | 33% | 35% | 33% | 30% | 33% | 34% | 8% | 26% | 28% | 21% | 22% |
70 | 89 | 98 | 172 | 189 | 193 | 144 | 192 | 210 | 283 | 325 | 137 | |
EPS in Rs | 7.80 | 9.83 | 10.88 | 19.08 | 20.92 | 21.44 | 15.96 | 21.27 | 23.25 | 31.36 | 35.99 | 15.16 |
Dividend Payout % | 0% | 20% | 23% | 16% | 19% | 19% | 25% | 19% | 22% | 19% | 17% | 20% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 10% |
3 Years: | 9% |
TTM: | -21% |
Compounded Profit Growth | |
---|---|
10 Years: | 5% |
5 Years: | -1% |
3 Years: | -13% |
TTM: | -56% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 6% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 14% |
3 Years: | 13% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 |
Reserves | 363 | 426 | 497 | 647 | 800 | 975 | 1,083 | 1,221 | 1,412 | 1,641 | 1,912 | 2,022 |
0 | 0 | 38 | 2 | 0 | 170 | 0 | 0 | 81 | 47 | 0 | 15 | |
253 | 268 | 298 | 452 | 636 | 840 | 867 | 881 | 1,106 | 1,652 | 2,006 | 1,698 | |
Total Liabilities | 706 | 785 | 923 | 1,191 | 1,526 | 2,075 | 2,040 | 2,192 | 2,690 | 3,431 | 4,008 | 3,825 |
64 | 63 | 87 | 129 | 209 | 226 | 371 | 416 | 544 | 592 | 668 | 991 | |
CWIP | 88 | 133 | 149 | 210 | 232 | 360 | 220 | 161 | 131 | 212 | 204 | 0 |
Investments | 98 | 176 | 96 | 92 | 62 | 24 | 213 | 117 | 84 | 136 | 33 | 160 |
455 | 412 | 591 | 761 | 1,022 | 1,465 | 1,236 | 1,498 | 1,931 | 2,491 | 3,103 | 2,675 | |
Total Assets | 706 | 785 | 923 | 1,191 | 1,526 | 2,075 | 2,040 | 2,192 | 2,690 | 3,431 | 4,008 | 3,825 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
122 | 143 | 14 | 142 | 123 | -15 | 513 | 53 | 202 | 277 | 140 | 163 | |
-110 | -146 | -25 | -65 | -75 | -139 | -314 | 24 | -238 | -183 | -1 | -178 | |
-13 | -10 | 16 | -89 | -20 | 132 | -215 | -60 | 44 | -90 | -98 | -35 | |
Net Cash Flow | -1 | -13 | 6 | -12 | 28 | -21 | -16 | 18 | 9 | 4 | 41 | -51 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 197 | 193 | 165 | 200 | 196 | 206 | 168 | 208 | 196 | 163 | 184 | 205 |
Inventory Days | 81 | 72 | 85 | 82 | 133 | 187 | 110 | 116 | 127 | 151 | 166 | 167 |
Days Payable | 165 | 191 | 144 | 215 | 223 | 223 | 200 | 211 | 203 | 194 | 203 | 163 |
Cash Conversion Cycle | 113 | 74 | 105 | 68 | 106 | 170 | 79 | 113 | 121 | 120 | 147 | 210 |
Working Capital Days | 104 | 76 | 100 | 93 | 100 | 139 | 74 | 116 | 113 | 92 | 105 | 171 |
ROCE % | 24% | 27% | 26% | 39% | 34% | 29% | 19% | 17% | 20% | 24% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2d - Audio Recording of Earning call for Q4 FY 2023-24
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 May - Results (both standalone & consolidated) as approved by the Board on 10th May, 2024 was published in Economic Times & Maharashtra Times on 11th May, …
-
Announcement under Regulation 30 (LODR)-Investor Presentation
10 May - Investor presentation on the Financial Result of the Company for the Year ended 31st March, 2024.
-
Appointment Of Additional Director (Non-Executive & Independent Director)
10 May - Company has appointed Mr. H. S. Upendra Kamath (DIN: 02648119), Mr. Shalin S. Divatia (DIN: 00749517), and Mr. Vinod Kumar Kathuria (DIN: 06662559) as an …
- Results - 31St March, 2024 10 May
Annual reports
Concalls
-
May 2024TranscriptNotesPPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Jul 2023Transcript PPT REC
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Jul 2022Transcript PPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Jul 2021Transcript PPT
-
May 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Oct 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020Transcript PPT
-
Jan 2020Transcript PPT
-
Oct 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Jul 2018Transcript PPT
-
May 2018Transcript PPT
-
Jan 2018Transcript PPT
-
Oct 2017Transcript PPT
-
Jul 2017TranscriptPPT
-
May 2017Transcript PPT
-
Jan 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptNotesPPT
-
Jan 2016Transcript PPT
Asset Light Business Model[1]
The company follows an asset light business model as they focus on Identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulation. The company outsources the manufacturing of AI's and other formulations and this has resulted in cost competitiveness across various geographies.